Riken Corporation

Takuya Tashiro

Kenji Mori

Masaru Taniguchi

Hiroshi Watarai

Masao Shiozaki

Ryusuke Nakagawa

Ken-ichi Fuhshuku

Tomokuni Shigeura

Ken-ichiro Seino

Kenichiro Seino

Ken-Ichi Fuhshuku

Ken-Ichiro Seino

The invention provides a compound effective as an antitumor active agent or vaccine adjuvant and an intermediate useful for the synthesis of the compound, as well as production methods thereof, and a medicament containing the novel compound. The compound is a carbamate glycolipid represented by the formula (I) wherein each symbol is as defined herein. The invention also provides a dendritic cell pulsed with the glycolipid.

Carbamate glycolipid and use thereof

The invention provides a compound represented by the formula (I) wherein Ris a hydrogen atom or a hydroxyl group; two Rare the same or different and each is a hydrogen atom or a hydroxyl group; Ris a hydrocarbon group having 8-14 carbon atoms, which optionally has substituent(s); and Ris a hydrocarbon group having 18-24 carbon atoms, which optionally has substituent(s), or a salt thereof. The invention also provides a method of treating an autoimmune disease or suppressing immunity by administering the aforementioned compound or a salt thereof to a patient in need thereof.

Hydroxylated KRN7000 analogue and use thereof

A compound represented by the following formula (1): wherein Ris an aldopyranose residue wherein the 6-hydroxyl group is optionally alkylated, Ris a Chydrocarbon group optionally having substituent(s), Ris a hydrogen atom or a Chydrocarbon group optionally having substituent(s), Ris a Chydrocarbon group optionally having substituent(s), X is an oxygen atom or &#x2014;CH&#x2014;, and Y is &#x2014;CH&#x2014;, &#x2014;CH(OH)&#x2014; or &#x2014;CH&#x2550;CH&#x2014;, or a salt thereof is useful for the prophylaxis or treatment of cancer or infection, since it can preferentially induce production of IFN-&#x3b3; of NKT cells.

Synthetic glycolipid and use thereof

The invention provides esterified &#x3b1;-galactosylceramides effective for cancer treatment and the like, and a medicament containing same. In particular, the invention relates to a compound represented by the formula (I): wherein Ris a hydrocarbon group having a carbon number of 1 to 30, Ris a hydrocarbon group having a carbon number of 1 to 20, Ris a hydrogen atom or hydrocarbon group having a carbon number of 1 to 5, Rand Rare the same or different and each is a hydrogen atom or a hydrocarbon group having a carbon number of 1 to 5, or Rand Rin combination form a divalent hydrocarbon group having a carbon number of 1 to 5, and optionally form a ring structure together with the adjacent ethylenedioxy, or a salt thereof.

Esterified &#x3b1;-galactosylceramide

The invention provides a glycolipid effective for cancer treatment and the like and a synthetic intermediate therefor, as well as a medicament containing the glycolipid and the like. The glycolipid is represented by the formula (1) or a salt thereof 

Glycolipid and use thereof

The invention provides a pseudoglycolipid effective for cancer treatment and the like and a novel synthesis intermediate therefor, as well as a medicament containing the pseudoglycolipid and the like. The inventive compound is represented by the formula (1), or a salt thereof, wherein each symbol is as defined in the specification.

Pseudoglycolipid and use thereof

The present invention relates to a compound represented by the following formula (1') wherein R is an aldopyranose residue, Ris a C2-18 hydrocarbon group optionally having substituent(s), Ris an acyl group, X is an oxygen atom, a sulfur atom or &#x2014;NH&#x2014;, and p is an integer of 0-4, or a salt thereof. The compound of the present invention has a specific immunoregulatory ability, and is useful for the prophylaxis or treatment of autoimmune diseases and the like.

Compound having cyclic structure and use thereof

The present invention provide a compound represented by the following formula (1) wherein each symbol is as defined in the specification, or a salt thereof. The compound of the present invention and a salt thereof can preferentially induce production of IL-4, which is one kind of cytokines that control action of immunocytes. Therefore, it is useful for the prophylaxis or treatment of autoimmune diseases, infectious diseases and the like, and prophylaxis or treatment of diseases caused by functional promotion of Th1 cells.

Growing community of inventors

Kanagawa, Japan

Takuya Tashiro